Literature DB >> 25546771

Considering the demand for and prioritization of intravenous immunoglobulin.

J S Orange1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25546771      PMCID: PMC4285500          DOI: 10.1111/cei.12520

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  8 in total

1.  Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project.

Authors:  Stephen Holding; Sujoy Khan; William A C Sewell; Stephen Jolles; Philip C Dore
Journal:  Ann Clin Biochem       Date:  2014-07-14       Impact factor: 2.057

2.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors:  Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal:  Clin Immunol       Date:  2010-08-01       Impact factor: 3.969

3.  Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.

Authors:  Jeffrey S Stonebraker; Albert Farrugia; Benjamin Gathmann; Jordan S Orange
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 4.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

5.  Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery.

Authors:  Vicki Modell; Megan Knaus; Fred Modell; Chaim Roifman; Jordan Orange; Luigi D Notarangelo
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

6.  Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.

Authors:  J S Orange; B H Belohradsky; M Berger; M Borte; J Hagan; S Jolles; R L Wasserman; J S Baggish; R Saunders; B Grimbacher
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

7.  Calculated globulin (CG) as a screening test for antibody deficiency.

Authors:  S Jolles; R Borrell; S Zouwail; A Heaps; H Sharp; M Moody; C Selwood; P Williams; C Phillips; K Hood; S Holding; T El Shanawany
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

8.  Prioritization of evidence-based indications for intravenous immunoglobulin.

Authors:  Jordan S Orange; Hans D Ochs; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2013-06-14       Impact factor: 8.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.